

HR 5850

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 29, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 6, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/5850>

Sponsor

Name: Rep. Mann, Tracey [R-KS-1]

Party: Republican • **State:** KS • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Moolenaar, John R. [R-MI-2]	R · MI		Sep 29, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 6, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary

No summary is currently available for this bill.

Actions Timeline

- **Oct 6, 2023:** Referred to the Subcommittee on Health.
- **Sep 29, 2023:** Introduced in House
- **Sep 29, 2023:** Referred to the House Committee on Energy and Commerce.